Respiratory failure & ventilation
Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial
Authors' conclusion
Early administration of interferon gamma might be cost-effective in critically ill patients
Study context
- Population
- Critically ill adults under mechanical ventilation
- Participants
- 109 participants
- Comparison
- Interferon gamma-1b vs placebo
- Primary endpoint
- Incremental cost-effectiveness ratio (ICER): adjusted cost per adjusted QALY gained (QALYs from EQ-5D-3L)
- Follow-up
- 90 days
Methodological detailsmulticentre, placebo-controlled, 90-day time horizon, collective perspective
- Multicentre
- Placebo-controlled
- 90-day time horizon
- Collective perspective
Primary result
As reported in the abstract
Cost-effectiveness
Difference in mean adjusted costs per patient
−1.638 €
95% CI €−17.534 to €11.968
in favor of interferon gamma-1b
Mean difference in adjusted Quality-Adjusted Life-Years (QALYs)
+ 0.019 QALYs
95% CI −0.005 to 0.043
Cost-effectiveness
- Probability interferon gamma-1b cost-effective, WTP €20k–€150k per QALY (base case)
- 0.60 to 0.71
Further findings
| Outcome | Interferon gamma-1b | Placebo | OR (CI) | P value | |
|---|---|---|---|---|---|
| All-cause mortality · Day 90 | 23.6% | 25% | 0.88 (0.40–1.93) | P = 0.67 | |
| 0.512Odds ratio (log scale) |
Original publication
Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial. J Intensive Care. Published 11 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →